Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Executive Summary
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems
You may also be interested in...
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Raptiva Withdrawal Shows Comparative Safety Focus From New, Decisive FDA
Market withdrawal of Genentech's psoriasis drug Raptiva (efalizumab) shows FDA under new leadership acting decisively on drug safety - especially in cases where comparable treatment alternatives exist
Genentech Aborts Raptiva Amidst Reports Of Fatal Brain Infection
Risk management program couldn't save psoriasis drug. Decision is final, firm says.